Biosimilars are large, complex molecules made from living organisms that are highly similar to their reference biologic and are administered in the same way, with the same strength and dosage, and clinically meaningful differences in safety, purity, and potency.

Although regularly used in other disorders, applying biosimilars in osteoporosis is a novel concept.  Join us as we discuss using biosimilars as an alternative treatment option for osteoporosis that may be safely integrated into clinical practice to deliver high quality care and positive effects on bone health.

Accreditation

EXCEL Continuing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

EXCEL Continuing Education designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Educational Objectives

At the conclusion of this conference, you should be able to:

• Define biosimilars and how these new agents can help close the treatment gap for managing individuals with osteoporosis and at increased risk of fractures
• Using patient cases from other disorders, explain how biosimilars have resulted in positive patient outcomes

Supporter